OTCMKTS:IPSEY Ipsen - IPSEY Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. $28.21 +0.10 (+0.36%) (As of 03/24/2023 08:52 PM ET) Add Compare Share Share Today's Range$28.21▼$28.2150-Day Range$25.84▼$29.4252-Week Range$21.17▼$32.51Volume200 shsAverage Volume821 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield0.85%Price Target$106.00 ProfileAnalyst RatingsChartCompetitorsDividendHeadlinesShort Interest Ipsen MarketRank™ ForecastAnalyst RatingHold2.27 Rating ScoreUpside/Downside275.8% Upside$106.00 Price TargetShort InterestHealthyDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth3.45%From $2.90 to $3.00 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.94 out of 5 stars 3.1 Analyst's Opinion Consensus RatingIpsen has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 3 buy ratings, 8 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $106.00, Ipsen has a forecasted upside of 275.8% from its current price of $28.21.Amount of Analyst CoverageIpsen has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverIpsen has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ipsen has recently decreased by 11.11%, indicating that investor sentiment is improving significantly. Previous Next 0.8 Dividend Strength Dividend YieldIpsen has a dividend yield of 0.85%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthIpsen does not have a long track record of dividend growth.Dividend SustainabilityBased on earnings estimates, Ipsen will have a dividend payout ratio of 8.00% next year. This indicates that Ipsen will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IPSEY. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Ipsen this week, compared to 1 article on an average week. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ipsen insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ipsen are expected to grow by 3.45% in the coming year, from $2.90 to $3.00 per share.Price to Book Value per Share RatioIpsen has a P/B Ratio of 2.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ipsen (OTCMKTS:IPSEY) StockIpsen SA manufactures pharmaceutical products for oncology, neuroscience, and rare diseases. It operates through the following segments: Specialty Care. The Specialty Care segment focuses on oncology with Somatuline, a somatostatin analog for the treatment of neuroendocrine tumors; Cabometyx, the single-agent treatment with significant improvement across all key efficacy endpoints in second-line renal cell carcinoma; Onivyde, a differentiated product with overall survival benefit addressing a high unmet medical need in pancreatic cancer; and Decapeptyl, an established and growing product in Europe and China for prostate cancer and rare diseases with Nutropin, a liquid formulation of recombinant human growth hormone and Increlex, a recombinant insulin-like growth factor of human origin. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France.Read More Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSEY Stock News HeadlinesMarch 16, 2023 | finanznachrichten.deIpsen Pharma: Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOPMarch 16, 2023 | finance.yahoo.comIpsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOPMarch 27, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 2, 2023 | uk.finance.yahoo.comIpsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolioFebruary 22, 2023 | finance.yahoo.comIpsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023February 9, 2023 | finanznachrichten.deIpsen Pharma: Ipsen presents strong full-year 2022 results and guidance for 2023February 9, 2023 | finance.yahoo.comIpsen presents strong full-year 2022 results and guidance for 2023January 27, 2023 | markets.businessinsider.comIpsen: CHMP Recommends Not To Grant Marketing Authorization For Palovarotene As Treatment For FOPMarch 27, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.January 27, 2023 | msn.comIpsen faces another setback for bone disorder drug with EMA panel's rejectionJanuary 27, 2023 | finance.yahoo.comIpsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.January 20, 2023 | msn.comIpsen presents full data showing 'survival benefit' in pancreatic cancer in phase 3 trialJanuary 20, 2023 | finance.yahoo.comIpsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GIJanuary 20, 2023 | msn.comPublic see pharma workers as Covid heroes, Ipsen survey findsJanuary 13, 2023 | realmoney.thestreet.com3 Potential Biotech Buyout TargetsJanuary 10, 2023 | bizjournals.comIpsen to buy liver disease drugmaker for $952MJanuary 9, 2023 | benzinga.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Albireo (ALBO)January 9, 2023 | msn.comAlbireo stock jumps 85% as Ipsen set to acquire it for ~$952MDecember 27, 2022 | msn.comIpsen says FDA rejected treatment for rare bone disorderDecember 23, 2022 | au.finance.yahoo.comIpsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressivaDecember 8, 2022 | finance.yahoo.comIpsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and ChemotherapyDecember 7, 2022 | technews.tmcnet.comEllucian's CEO Laura Ipsen Highlighted in Top 50 Women Leaders in SaaS ListNovember 9, 2022 | seekingalpha.comMerrimack jumps 183% as partner Ipsen says pancreatic cancer trial met main goalNovember 9, 2022 | seekingalpha.comIpsen Onivyde combo meets trial's survival goal in untreated pancreatic cancer patientsOctober 27, 2022 | finance.yahoo.comIpsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year GuidanceOctober 25, 2022 | markets.businessinsider.comIpsen : FDA Postpones Palovarotene Advisory Committee MeetingSeptember 24, 2022 | msn.comIpsen set to invest extra €15m in DublinSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSEY Company Calendar Today3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:IPSEY CUSIPN/A CIKN/A Webwww.ipsen.com Phone(315) 833-5000Fax33-01-58-33-50-01Employees5,700Year FoundedN/APrice Target and Rating Average Stock Price Forecast$106.00 High Stock Price Forecast$142.00 Low Stock Price Forecast$86.00 Forecasted Upside/Downside+275.8%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.58 Sales & Book Value Annual Sales$3.33 billion Price / SalesN/A Cash Flow$3.51 per share Price / Cash Flow8.03 Book Value$9.72 per share Price / Book2.90Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.98 Key ExecutivesDavid G. LoewChief Executive Officer & DirectorAymeric Le ChatelierChief Financial Officer & Executive Vice PresidentAidan MurphyExecutive Vice President-Technical OperationsHoward MayerExecutive Vice President-Research & DevelopmentSteven HildemannChief Medical Officer & Executive Vice PresidentKey CompetitorsBG MedicineOTCMKTS:BGMDFluoroPharma MedicalOTCMKTS:FPMIHemagen DiagnosticsOTCMKTS:HMGNResponse GeneticsOTCMKTS:RGDXQ[email protected] TechnologyOTCMKTS:LPTCView All Competitors IPSEY Stock - Frequently Asked Questions Should I buy or sell Ipsen stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last twelve months. There are currently 8 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IPSEY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPSEY, but not buy additional shares or sell existing shares. View IPSEY analyst ratings or view top-rated stocks. What is Ipsen's stock price forecast for 2023? 11 equities research analysts have issued 1 year price objectives for Ipsen's shares. Their IPSEY share price forecasts range from $86.00 to $142.00. On average, they expect the company's share price to reach $106.00 in the next year. This suggests a possible upside of 275.8% from the stock's current price. View analysts price targets for IPSEY or view top-rated stocks among Wall Street analysts. How have IPSEY shares performed in 2023? Ipsen's stock was trading at $26.88 at the start of the year. Since then, IPSEY shares have increased by 4.9% and is now trading at $28.21. View the best growth stocks for 2023 here. Are investors shorting Ipsen? Ipsen saw a decrease in short interest in March. As of March 15th, there was short interest totaling 1,600 shares, a decrease of 11.1% from the February 28th total of 1,800 shares. Based on an average trading volume of 1,600 shares, the short-interest ratio is currently 1.0 days. View Ipsen's Short Interest. How often does Ipsen pay dividends? What is the dividend yield for Ipsen? Ipsen declared a dividend on Friday, May 27th. Shareholders of record on Wednesday, June 1st will be paid a dividend of $0.2269 per share on Thursday, June 9th. This represents a yield of 0.88%. The ex-dividend date of this dividend is Tuesday, May 31st. Read our dividend analysis for IPSEY. Is Ipsen a good dividend stock? Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.24 per share and currently has a dividend yield of 0.85%. Read our dividend analysis for IPSEY. What is Ipsen's stock symbol? Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY." How do I buy shares of Ipsen? Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ipsen's stock price today? One share of IPSEY stock can currently be purchased for approximately $28.21. How many employees does Ipsen have? The company employs 5,700 workers across the globe. How can I contact Ipsen? Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The official website for the company is www.ipsen.com. The company can be reached via phone at (315) 833-5000, via email at investor.relations@ipsen.com, or via fax at 33-01-58-33-50-01. This page (OTCMKTS:IPSEY) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.